CL2014002062A1 - Compuesto de moleculas pequeñas que inhiben cdk8 y cdk19, excluyendo cortistatina a y otros; formulacion farmceutica; un método para tratar a un mamifero que tiene una enfermedad relacionada con cdk1 como e. de alzheimer, otras demencias, amiloidosis, y un metodo para quimioproteger un paciente que padece cancer de ovario o mama, entre otros. - Google Patents

Compuesto de moleculas pequeñas que inhiben cdk8 y cdk19, excluyendo cortistatina a y otros; formulacion farmceutica; un método para tratar a un mamifero que tiene una enfermedad relacionada con cdk1 como e. de alzheimer, otras demencias, amiloidosis, y un metodo para quimioproteger un paciente que padece cancer de ovario o mama, entre otros.

Info

Publication number
CL2014002062A1
CL2014002062A1 CL2014002062A CL2014002062A CL2014002062A1 CL 2014002062 A1 CL2014002062 A1 CL 2014002062A1 CL 2014002062 A CL2014002062 A CL 2014002062A CL 2014002062 A CL2014002062 A CL 2014002062A CL 2014002062 A1 CL2014002062 A1 CL 2014002062A1
Authority
CL
Chile
Prior art keywords
chemoprotect
cdk19
cortistatin
cdk1
dementias
Prior art date
Application number
CL2014002062A
Other languages
English (en)
Spanish (es)
Inventor
Igor B Robinson
Donald C Porter
Mark P Wentland
Original Assignee
Senex Biotechnology Inc Us Us
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Senex Biotechnology Inc Us Us filed Critical Senex Biotechnology Inc Us Us
Publication of CL2014002062A1 publication Critical patent/CL2014002062A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/70—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings condensed with carbocyclic rings or ring systems
    • C07D239/72—Quinazolines; Hydrogenated quinazolines
    • C07D239/86—Quinazolines; Hydrogenated quinazolines with hetero atoms directly attached in position 4
    • C07D239/94—Nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57515—Immunoassay; Biospecific binding assay; Materials therefor for cancer of the breast
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57545—Immunoassay; Biospecific binding assay; Materials therefor for cancer of the ovaries
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/106—Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/118—Prognosis of disease development
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/158—Expression markers
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/46—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans from vertebrates
    • G01N2333/47—Assays involving proteins of known structure or function as defined in the subgroups
    • G01N2333/4701—Details
    • G01N2333/4739—Cyclin; Prad 1
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/90—Enzymes; Proenzymes
    • G01N2333/91—Transferases (2.)
    • G01N2333/912—Transferases (2.) transferring phosphorus containing groups, e.g. kinases (2.7)
    • G01N2333/91205—Phosphotransferases in general

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • Urology & Nephrology (AREA)
  • Analytical Chemistry (AREA)
  • Pathology (AREA)
  • Hematology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Physics & Mathematics (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Oncology (AREA)
  • Virology (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Genetics & Genomics (AREA)
  • Hospice & Palliative Care (AREA)
  • Food Science & Technology (AREA)
  • Cell Biology (AREA)
  • Communicable Diseases (AREA)
  • General Physics & Mathematics (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
CL2014002062A 2012-02-02 2014-08-01 Compuesto de moleculas pequeñas que inhiben cdk8 y cdk19, excluyendo cortistatina a y otros; formulacion farmceutica; un método para tratar a un mamifero que tiene una enfermedad relacionada con cdk1 como e. de alzheimer, otras demencias, amiloidosis, y un metodo para quimioproteger un paciente que padece cancer de ovario o mama, entre otros. CL2014002062A1 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201261594023P 2012-02-02 2012-02-02
US201261673419P 2012-07-19 2012-07-19

Publications (1)

Publication Number Publication Date
CL2014002062A1 true CL2014002062A1 (es) 2015-03-20

Family

ID=47716178

Family Applications (1)

Application Number Title Priority Date Filing Date
CL2014002062A CL2014002062A1 (es) 2012-02-02 2014-08-01 Compuesto de moleculas pequeñas que inhiben cdk8 y cdk19, excluyendo cortistatina a y otros; formulacion farmceutica; un método para tratar a un mamifero que tiene una enfermedad relacionada con cdk1 como e. de alzheimer, otras demencias, amiloidosis, y un metodo para quimioproteger un paciente que padece cancer de ovario o mama, entre otros.

Country Status (16)

Country Link
US (2) US9321737B2 (enExample)
EP (2) EP2809324B1 (enExample)
JP (1) JP6193268B2 (enExample)
KR (1) KR20150023223A (enExample)
CN (1) CN104363913B (enExample)
AU (1) AU2013214783B2 (enExample)
BR (1) BR112014019052A8 (enExample)
CL (1) CL2014002062A1 (enExample)
CO (1) CO7151516A2 (enExample)
EA (2) EA028595B1 (enExample)
GE (2) GEP20186818B (enExample)
MY (1) MY165446A (enExample)
PH (1) PH12014501862A1 (enExample)
SG (1) SG11201404596UA (enExample)
UA (1) UA117342C2 (enExample)
WO (1) WO2013116786A1 (enExample)

Families Citing this family (40)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP6324380B2 (ja) 2012-07-27 2018-05-16 バイオジェン・エムエイ・インコーポレイテッドＢｉｏｇｅｎ ＭＡ Ｉｎｃ． Ｓ１ｐ調節剤および／またはａｔｘ調節剤である化合物
RU2015107550A (ru) * 2012-08-23 2016-10-10 Ф. Хоффманн-Ля Рош Аг Новые фенилпиридин/пиразинамиды для лечения рака
KR20160014568A (ko) 2012-11-01 2016-02-11 유니버시티 오브 싸우스 캐롤라이나 전립선암을 치료하는 방법
WO2014134169A1 (en) * 2013-02-26 2014-09-04 Senex Biotechnology, Inc. Inhibitors of cdk8/19 for use in treating estrogen receptor positive breast cancer
AU2014369834B2 (en) 2013-12-24 2018-12-20 President And Fellows Of Harvard College Cortistatin analogues and syntheses and uses thereof
JP6529085B2 (ja) * 2014-04-18 2019-06-12 武田薬品工業株式会社 複素環化合物
WO2016018511A2 (en) * 2014-06-10 2016-02-04 University Of South Carolina Methods and compositions for treatment of her-positive cancers
US20210322651A1 (en) 2014-12-18 2021-10-21 Senex Biotechnology, Inc. Suppression of neointimal formation following vascular surgeru using cdk8 inhibitors
WO2016182932A1 (en) 2015-05-08 2016-11-17 President And Fellows Of Harvard College Cortistatin analogues, syntheses, and uses thereof
RU2017142394A (ru) * 2015-05-08 2019-06-10 Президент Энд Феллоус Оф Гарвард Колледж Целевой отбор пациентов для лечения производными кортистатина
EP3316889A4 (en) 2015-07-01 2018-11-14 President and Fellows of Harvard College Cortistatin analogues and syntheses and uses thereof
AU2016348659B2 (en) 2015-11-03 2022-07-28 Apriligen, Inc. Compounds for treatment of hypoproliferative disorders
WO2017091836A1 (en) * 2015-11-25 2017-06-01 University Of South Carolina Enhancement of cytarabine activity by inhibiting cdk8/19
JP7198489B2 (ja) * 2016-03-23 2023-01-04 国立大学法人 岡山大学 リン酸化ｓａｒｍ１、抗体、ｓａｒｍ１リン酸化阻害剤、神経変性疾患の予防又は治療薬、スクリーニング方法、ｓａｒｍ１改変体及び使用
US11285144B2 (en) 2016-08-03 2022-03-29 The Broad Institute, Inc. Use of CDK8 inhibitors to treat diseases of inflammation and autoimmunity
CN114921468A (zh) * 2017-01-30 2022-08-19 国立大学法人京都大学 新型化合物以及调节性t细胞的制造方法
WO2018151633A1 (ru) * 2017-02-20 2018-08-23 Закрытое Акционерное Общество "Биокад" Способы получения производных 4-(((нафталин-2-ил)алкил)амино)хинозалин-6-карбонитрилов
WO2018156858A1 (en) * 2017-02-23 2018-08-30 University Of South Carolina Use of cdk8/19 inhibitors for treatment of established colon cancer hepatic metastasis
EP3591040A4 (en) * 2017-03-03 2020-11-11 Kyoto University METHOD OF PRODUCTION OF PANCREATIC PROGENITOR CELLS
RU2641001C1 (ru) * 2017-04-03 2018-01-15 Закрытое Акционерное Общество "Биокад" Соли 4-((2-(6-(4-метилпиперазин-1-карбонил)нафталин-2-ил)этил)амино)хиназолин-6-карбонитрила и фармацевтическая композиция
AU2018249154A1 (en) * 2017-04-03 2019-11-21 Kyoto Pharmaceutical Industries, Ltd. Novel cyclin-dependent kinase 8 and/or 19 inhibitor
JP7392954B2 (ja) * 2017-09-18 2023-12-06 シーゼット・バイオハブ・エスエフ・リミテッド・ライアビリティ・カンパニー トリプルネガティブ乳癌の治療方法
WO2019068613A1 (en) 2017-10-02 2019-04-11 Boehringer Ingelheim International Gmbh NOVEL [1,6] NAPHTHYRIDINE COMPOUNDS AND DERIVATIVES AS CDK8 / CDK19 INHIBITORS
RU2763347C2 (ru) * 2018-03-01 2021-12-28 Закрытое Акционерное Общество "Биокад" Новые ингибиторы cdk8/19
US11014906B2 (en) 2018-08-21 2021-05-25 University Of South Carolina Quinoline-based compounds and methods of inhibiting CDK8/19
US12281080B2 (en) 2018-08-21 2025-04-22 University Of South Carolina Quinoline-based compounds and methods of inhibiting CDK8/19
CN113677341B (zh) 2019-02-01 2024-07-05 南卡罗莱纳大学 双环吡啶组合物及其用于癌症治疗的方法
JP7805009B2 (ja) 2020-11-20 2026-01-23 オリヅルセラピューティクス株式会社 成熟化剤
TW202246489A (zh) 2021-02-09 2022-12-01 日商千紙鶴治療公司 成熟化劑
EP4313050A4 (en) * 2021-03-25 2025-02-12 University of South Carolina CDK8/19 INHIBITORS FOR CYTOKINIC STORM TREATMENT
AU2022349176A1 (en) 2021-09-27 2024-04-11 Kyoto University Method for producing t cell
US20250018033A1 (en) 2021-11-24 2025-01-16 Regcell Co., Ltd. Human inducibility controllable t-cell and method for preparing same
MX2024006370A (es) 2021-11-24 2024-08-19 Regcell Co Ltd Composicion farmaceutica para tratar o prevenir trastornos relacionados con celulas t.
CN119256076A (zh) 2022-03-23 2025-01-03 国立大学法人京都大学 用于产生调节性t细胞的方法
AU2023262842A1 (en) 2022-04-25 2024-09-12 Orizuru Therapeutics, Inc. Maturing agent having both of alk5 inhibitory activity and cdk8/19 inhibitory activity
WO2024014497A1 (ja) 2022-07-14 2024-01-18 オリヅルセラピューティクス株式会社 細胞移植用のフィブリンゲルシート
EP4596684A1 (en) 2022-09-26 2025-08-06 Regcell Co., Ltd. Induced regulatory t cells containing chimeric antigen receptor (car)
EP4600352A1 (en) 2022-09-26 2025-08-13 Kyoto University T cell production method
KR20250140618A (ko) 2023-02-08 2025-09-25 레그셀 가부시키가이샤 천포창을 치료 또는 예방하기 위한 의약 조성물
JPWO2024204553A1 (enExample) 2023-03-29 2024-10-03

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6046206A (en) * 1995-06-07 2000-04-04 Cell Pathways, Inc. Method of treating a patient having a precancerous lesions with amide quinazoline derivatives
PL342447A1 (en) * 1997-10-27 2001-06-04 Agouron Pharma Substituted 4-amino thiazol-2-yl compounds as inhibitors of cyclin-dependent kinases
US6440959B1 (en) * 1999-04-21 2002-08-27 Hoffman-La Roche Inc. Pyrazolobenzodiazepines
US20040180844A1 (en) 2003-03-10 2004-09-16 Fesik Stephen W. Method of killing cancer cells
US20040180848A1 (en) 2003-03-10 2004-09-16 Fesik Stephen W. Method of killing cancer cells
BRPI0409241A (pt) * 2003-04-10 2006-03-28 Pfizer compostos bicìclicos como antagonistas do receptor de nr2b, composições farmacêuticas compreendendo os mesmos e seu uso
US20080033000A1 (en) * 2006-05-15 2008-02-07 Senex Biotechnology, Inc. Identification of CDKI pathway inhibitors
US8598344B2 (en) 2009-11-30 2013-12-03 Senex Biotechnology CDKI pathway inhibitors and uses thereof

Also Published As

Publication number Publication date
EA201791284A1 (ru) 2017-10-31
BR112014019052A8 (pt) 2017-07-11
GEP201706688B (en) 2017-06-26
AU2013214783A1 (en) 2014-08-28
US20170071942A1 (en) 2017-03-16
EP3431087A1 (en) 2019-01-23
EP2809324B1 (en) 2018-08-01
EA201491399A1 (ru) 2015-04-30
US9321737B2 (en) 2016-04-26
EA032429B1 (ru) 2019-05-31
CN104363913B (zh) 2018-08-21
KR20150023223A (ko) 2015-03-05
CO7151516A2 (es) 2014-12-29
WO2013116786A1 (en) 2013-08-08
CN104363913A (zh) 2015-02-18
US10993945B2 (en) 2021-05-04
US20140038958A1 (en) 2014-02-06
PH12014501862A1 (en) 2014-11-24
JP6193268B2 (ja) 2017-09-06
SG11201404596UA (en) 2014-10-30
EA028595B1 (ru) 2017-12-29
JP2015506376A (ja) 2015-03-02
AU2013214783B2 (en) 2017-07-06
UA117342C2 (uk) 2018-07-25
MY165446A (en) 2018-03-22
GEP20186818B (en) 2018-02-12
EP2809324A1 (en) 2014-12-10
BR112014019052A2 (enExample) 2017-06-20

Similar Documents

Publication Publication Date Title
CL2014002062A1 (es) Compuesto de moleculas pequeñas que inhiben cdk8 y cdk19, excluyendo cortistatina a y otros; formulacion farmceutica; un método para tratar a un mamifero que tiene una enfermedad relacionada con cdk1 como e. de alzheimer, otras demencias, amiloidosis, y un metodo para quimioproteger un paciente que padece cancer de ovario o mama, entre otros.
MX376047B (es) Inhibidores de desmetilasa-1 especifica de lisina.
EA201790951A1 (ru) Производные гидроксиалкилзамещенного фенилтриазола и их применение
NI201600165A (es) Inhibidores de desmetilasa 1 específica a lisina
CL2018000318A1 (es) Compuestos derivados de piridinona, inhibidores de bromodominio; composición farmacéutica que los comprende; y su uso en el tratamiento de enfermedades del cáncer. (solicitud divisional 201600925)
EA201591591A1 (ru) Соединения карбазола, применяемые в качестве ингибиторов бромодомена
CL2017000521A1 (es) Inhibidores de desmetilasa-1 específica a lisina
GT201600123A (es) Inhibidores de syk
EA201692513A1 (ru) Ингибиторы лизин-специфической деметилазы-1
EA201790085A1 (ru) Ингибиторы лизин-специфической деметилазы-1
BR112015020466A8 (pt) inibidores de cdc7, seus usos, e composição farmacêutica
CU20150163A7 (es) DERIVADOS DE 5-HETEROARIL-4-FENIL-4,5-DIHIDROPIRROLO(3,4-c)PIRAZOL-6-ONA ACTIVOS COMO INHIBIDORES DE BET
PH12016500024A1 (en) Bromodomain inhibitor
MX2020010412A (es) Inhibidores de tirosina quinasa de bruton.
MX2019010422A (es) Uso de derivados de pirazolopirimidina para el tratamiento de trastornos relacionados con la fosfoinositida 3-cinasa delta.
MY188934A (en) Labeled inhibitors of prostate specific membrane antigen (psma), their use as imaging agents and pharmaceutical agents for the treatment of prostate cancer
MX2015016277A (es) Tratamiento de canceres utilizando moduladores de la isoforma pi3 cinasa.
EA201490194A1 (ru) Комбинированная терапия, включающая ингибитор cdk4/6 и ингибитор pi3k для применения в лечении рака
MD20150085A2 (ro) Inhibitori ai histon-demetilazelor
CL2016000241A1 (es) Formulación de inhibidores de la syk.
BR112016015236A2 (pt) inibidores de serina/treonina quinase
HN2012000023A (es) Compuestos y composiciones para el tratamiento de enfermedades parasitarias
EA201790082A1 (ru) Ингибиторы лизин-специфической демитилазы-1
MX2022010638A (es) Inhibidores de pde9 para el tratamiento de enfermedades perifericas.
CL2014001838A1 (es) Compuestos derivados de fluormetil-5,6-dihidro-4h-[1,3]oxazin-2-ilamina, como inhibidores de la bace1; su proceso de obtencion; composicion farmaceutica que los contiene; y su uso para el tratamiento terapeutico y/o profilactico de la enfermedad de alzheimer, esclerosis lateral amiotrofica, cancer, enfermedades cardiovasculares y enfermedades gastrointestinales, entre otras.